Cardiovascular diseases research group (BIO-HEART)

Summary

This group focusses on clinical research in the area of cardiovascular diseases and risks, and has extensive experience in a highly relevant field, as cardiovascular diseases remain the main cause of mortality among both women and men in the Western world.
The group studies new surgical and pharmacological treatments for improving survival and recovery of patients affected by these diseases. It has extensive experience in the study of drugs which prevent platelet aggregation in the blood, specifically.

2089

Publications

Strategic lines

Selected Publications

Raposeiras Roubin,S;Amat Santos,IJ;Rossello,X;González Ferreiro,R;González Bermúdez,I;Lopez Otero,D;Nombela Franco,L et al, Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation., N Engl J Med, 2025;392(14):1396-1405, doi:10.1056/NEJMoa2500366
Vaduganathan,M;Claggett,BL;Chatur,S;Desai,AS;Jhund,PS;Vardeny,O;Merkely,B et al, Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction, Nat Med, 2025;32(1):325-331, doi:10.1038/s41591-025-04037-3
Sanchis,J;Bueno,H;Ariza Solé,A, Does revascularization improve survival in adult frail patients with acute coronary syndrome?, Eur. Heart J., 2025;46(7):2598-2599, doi:10.1093/eurheartj/ehaf275
Power,JR;Dolladille,C;Ozbay,B;Procureur,A;Ederhy,S;Palaskas,NL;Lehmann,LH et al, Immune checkpoint inhibitor-associated myocarditis: a novel risk score., Eur. Heart J., 2025;doi:10.1093/eurheartj/ehaf315
Peretto,G;Merlo,M;Ambrosi,A;Bacigalupi,E;Villatore,A;Molinari,L;Anguera,I et al, Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score., Eur. Heart J., 2025;47(1):94-106, doi:10.1093/eurheartj/ehaf477

Selected Projects

ALXN2220-ATTR-CM-301. Estudio multicéntrico de fase 3, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad del agotador de amiloide ALXN2220 en participantes adultos con miocardiopatía amilida por transtiretina (ATTR-CM).. Alexion Pharmaceuticals, Inc. Budget: 1.750.820€. 2024- . PI: JOSE GONZALEZ COSTELLO.
AG10-501. Estudio de fase 3, aleatorizado, multicéntrico, con doble enmascaramiento y comparativo con placebo de acoramidis para la prevención de la amiloidosis por transtiretina en los jóvenes (Ensayo ACT-EARLY). Eidos Therapeutics, Inc.. Budget: 682.920€. 2025- . PI: JOSE GONZALEZ COSTELLO.
20230227. A Phase 3 Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF).. Amgen Inc. Budget: 670.215€. 2025- . PI: JOSEP COMÍN COLET.
LIB003-007. Estudio de extensión abierto de Fase 3 para evaluar la eficacia y la seguridad a largo plazo de LIB003 en pacientes con Hipercolesterolemia familiar Homocigótica y Heterocigótica, Enfermedad Cardiovascular o Alto Riesgo de Enfermedad Cardiovascular, en tratamiento hipolipemiante estable que precisan una reducción adicional del colesterol unido a las lipoproteínas de baja densidad (LIBERATE-OLE). MEDPACE CLINICAL RESEARCH, LLC. Budget: 401.128€. 2022-2026. PI: JAVIER PINTO SALA.
101194778. bridGing gaps in caRdiAC health managEment. COMISSIÓ EUROPEA. Budget: 340.460€. 2025-2029. PI: JOSEP COMÍN COLET.